As a specialized genetic medicine and rare disease enterprise, Krystal Biotech competes with various biotechnology and pharmaceutical firms focusing on advanced gene therapies, rare dermatological disorders, and targeted oncology treatments. While its flagship product currently holds a unique position as the first-ever approved redosable topical gene therapy for its specific indication, the company faces broad competitive pressure from other genomic medicine developers utilizing viral vectors, mRNA technologies, and CRISPR-based gene editing systems. Competitors range from large-scale biopharmaceutical giants investing heavily in rare disease pipelines to nimble, early-stage biotech startups attempting to engineer alternative delivery mechanisms for dermatology, pulmonary diseases, and localized tumor immunotherapies.